Biotech start-up Normunity, Inc. has exited stealth with a $65 million Series A to create a new class of medicines that target novel I-O mechanisms, which free the body’s normal immunity against ...

Thanks for subscribing! Look out for your first newsletter in your inbox soon! The best of London for free. Sign up for our email to enjoy London without spending a thing (as well as some options when ...